INHIBIKASE THERAPEUTICS INC IKT
COM · Common Stock · CUSIP 45719W106
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- HeadquartersWilmington, DE
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $3.62.
Trends to Q2 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 25 |
| Q4 2022 | 20 |
| Q1 2023 | 18 |
| Q2 2023 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 9 | 12 |
| Q1 2023 | 7 | 6 |
| Q2 2023 | 0 | 18 |
Biggest buyers
| None |
Biggest sellers
| ARMISTICE CAPITAL, LLC | Sold out | -3.0m |
| VANGUARD GROUP INC | Sold out | -530.3k |
| BLAIR WILLIAM & CO/IL | Sold out | -276.0k |
| Redmond Asset Management, LLC | Sold out | -125.8k |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -89.0k |
| HAMILTON LANE ADVISORS LLC | Reduced | -69.0k |
| RENAISSANCE TECHNOLOGIES LLC | Sold out | -67.3k |
| STATE STREET CORP | Sold out | -60.5k |
| Koshinski Asset Management, Inc. | Sold out | -57.7k |
| Bank of New York Mellon Corp | Sold out | -39.0k |
Insider purchases and sales in Q2 2023
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q3 2021 | 0 | — | 0 | — | — |
| Q4 2021 | 1 | $46.6k | 0 | — | — |
| Q1 2022 | 0 | — | 0 | — | — |
| Q2 2022 | 2 | $13.4k | 0 | — | — |
| Q3 2022 | 1 | $4.0k | 0 | — | — |
| Q4 2022 | 0 | — | 0 | — | — |
| Q1 2023 | 0 | — | 0 | — | — |
| Q2 2023 | 0 | — | 0 | — | — |
None reported in Q2 2023.
Holders, Q2 2023
| Manager | Shares | Change |
|---|---|---|
| HAMILTON LANE ADVISORS LLC 0.01% of their portfolio | 13.8k $50.0k | Reduced -69.0k |